Recent advances in trimethoxyphenyl (TMP) based tubulin inhibitors targeting the colchicine binding site

Microtubules (composed of α- and β-tubulin heterodimers) play a pivotal role in mitosis and cell division, and are regarded as an excellent target for chemotherapeutic agents to treat cancer. There are four unique binding sites in tubulin to which taxanes, vinca alkaloids, laulimalide and colchicine...

Full description

Saved in:
Bibliographic Details
Published in:European journal of medicinal chemistry 2018-05, Vol.151, p.482-494
Main Authors: Li, Ling, Jiang, Sibo, Li, Xiaoxun, Liu, Yao, Su, Jing, Chen, Jianjun
Format: Article
Language:English
Subjects:
Cancer
Colchicine binding site
Trimethoxyphenyl (TMP)
Tubulin inhibitors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Microtubules (composed of α- and β-tubulin heterodimers) play a pivotal role in mitosis and cell division, and are regarded as an excellent target for chemotherapeutic agents to treat cancer. There are four unique binding sites in tubulin to which taxanes, vinca alkaloids, laulimalide and colchicine bind respectively. While several tubulin inhibitors that bind to the taxane or vinca alkaloid binding sites have been approved by FDA, currently there are no FDA approved tubulin inhibitors targeting the colchicine binding site. Tubulin inhibitors that bind to the colchicine binding site have therapeutic advantages over taxanes and vinca alkaloids, for example, they can be administered orally, have less drug-drug interaction potential, and are less prone to develop multi-drug resistance. Typically, tubulin inhibitors that bind to the colchicine binding site bear the trimethoxyphenyl (TMP) moiety which is essential for interaction with tubulin. Over the last decade, a variety of molecules bearing the TMP moiety have been designed and synthesized as tubulin inhibitors for cancer treatment. In this review, we focus on the TMP analogs that are designed based on CA-4, indole, chalcone, colchicine and natural product scaffolds which are known to interact with the colchicine binding site in tubulin. The challenges and future direction of the TMP based tubulin inhibitors are also discussed in detail. [Display omitted] •Crystal structures of tubulin with trimethoxyphenyl (TMP) analogs summarized.•Binding interactions between TMP analogs and tubulin discussed.•TMP analogs based on CA-4, indole, chalcone, colchicine and natural product scaffsolds.
ISSN:0223-5234
1768-3254
DOI:10.1016/j.ejmech.2018.04.011